Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FOUAD J MOAWAD

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1447221007
CMS profile
945095
Location
LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$219,727.52

202 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FOUAD J MOAWAD

NPI 1447221007 · CMS profile ID 945095

Allopathic & Osteopathic Physicians / Internal Medicine

LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447221007?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FOUAD J MOAWAD, NPI 1447221007, CMS profile ID 945095. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447221007?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). FOUAD J MOAWAD, NPI 1447221007, CMS profile ID 945095. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447221007?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
FOUAD J MOAWAD, NPI 1447221007, CMS profile ID 945095, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1447221007?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

202 matching records · $219,727.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 202 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 202.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $4,605.0005/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305605 CMS
Regeneron Healthcare Solutions, Inc. $6,447.0005/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305611 CMS
Regeneron Healthcare Solutions, Inc. $21.0405/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305599 CMS
Regeneron Healthcare Solutions, Inc. $784.3705/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305593 CMS
Merck Sharp & Dohme LLC $23.0605/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048254727 CMS
Regeneron Healthcare Solutions, Inc. $120.7905/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305587 CMS
ABBVIE INC. $14.9805/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997931421 CMS
Regeneron Healthcare Solutions, Inc. $6,447.0005/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305581 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.4605/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055494555 CMS
Regeneron Healthcare Solutions, Inc. $168.1105/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305575 CMS
Regeneron Healthcare Solutions, Inc. $215.9205/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305569 CMS
Regeneron Healthcare Solutions, Inc. $170.1105/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305557 CMS
Regeneron Healthcare Solutions, Inc. $124.9905/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305563 CMS
Regeneron Healthcare Solutions, Inc. $29.5405/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305553 CMS
Regeneron Pharmaceuticals, Inc. $59.7205/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000025761 CMS
Regeneron Healthcare Solutions, Inc. $128.9805/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305547 CMS
Regeneron Healthcare Solutions, Inc. $614.0605/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305541 CMS
Regeneron Healthcare Solutions, Inc. $1,535.0005/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305535 CMS
Braintree Laboratories, Inc. $14.7805/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006456925 CMS
Regeneron Healthcare Solutions, Inc. $338.3505/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305527 CMS
Celgene Corporation $12.7005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015243623 CMS
Regeneron Healthcare Solutions, Inc. $75.8805/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305522 CMS
Regeneron Healthcare Solutions, Inc. $6,447.0004/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305515 CMS
Regeneron Healthcare Solutions, Inc. $189.0004/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305503 CMS
Regeneron Healthcare Solutions, Inc. $189.0004/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305509 CMS
Regeneron Healthcare Solutions, Inc. $179.4104/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305497 CMS
GENZYME CORPORATION $255.1604/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879525 CMS
GENZYME CORPORATION $114.1704/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879775 CMS
GENZYME CORPORATION $6,447.0004/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879779 CMS
GENZYME CORPORATION $764.1004/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879783 CMS
GENZYME CORPORATION $49.9204/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879787 CMS
GENZYME CORPORATION $199.0904/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879789 CMS
Regeneron Healthcare Solutions, Inc. $23.1404/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305493 CMS
ABBVIE INC. $18.6304/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997931419 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $25.5604/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057194947 CMS
Regeneron Healthcare Solutions, Inc. $498.3303/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305487 CMS
GENZYME CORPORATION $2,149.0003/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879735 CMS
Regeneron Healthcare Solutions, Inc. $55.9003/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305469 CMS
Regeneron Healthcare Solutions, Inc. $56.9103/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305473 CMS
Regeneron Healthcare Solutions, Inc. $14.7703/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305477 CMS
Regeneron Healthcare Solutions, Inc. $224.6203/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305483 CMS
Regeneron Healthcare Solutions, Inc. $225.6003/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305457 CMS
Regeneron Healthcare Solutions, Inc. $220.9803/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305463 CMS
Regeneron Healthcare Solutions, Inc. $6,447.0003/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305451 CMS
Regeneron Healthcare Solutions, Inc. $219.8603/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305445 CMS
GENZYME CORPORATION $32.1703/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879711 CMS
Regeneron Healthcare Solutions, Inc. $66.1603/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999305439 CMS
GENZYME CORPORATION $245.8403/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879521 CMS
GENZYME CORPORATION $165.6703/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879739 CMS
GENZYME CORPORATION $6,447.0003/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049879747 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,012.33 33
PY2020 $3,549.26 10
PY2021 $13,961.61 41
PY2022 $89,166.84 100
PY2023 $219,727.52 202
PY2024 $192,277.83 184
PY2025 $205,553.24 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $37,655.55 26
PY2024 Principal investigator $39,968.74 10
PY2022 Principal investigator $20,216.48 11
PY2021 Principal investigator $30,992.69 11
PY2020 Principal investigator $21,307.50 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $973.21 10/23/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 10/09/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,950.00 09/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 09/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 08/14/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,687.38 08/14/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 06/24/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 06/24/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.83 06/24/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 06/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 06/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,200.00 06/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,000.00 06/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,684.69 04/08/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,988.07 04/01/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 03/11/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 02/11/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $908.40 01/29/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $757.35 01/17/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,303.27 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.60 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $132.60 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $165.10 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.70 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.30 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136949